Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Gastroenterology | Infections and Infectious Diseases | Family Medicine
Clinical Trials: Irritable Bowel Syndrome (IBS)
A listing of clinical trials currently looking for volunteers to enroll in Irritable Bowel Syndrome (IBS) studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Birmingham : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Birmingham : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Birmingham : Radiant Research - Birmingham
Clinical Research for Irritable Bowel Syndrome (IBS)
Birmingham : Radiant Research - Birmingham
Clinical Research Opportunity for People with Irritable Bowel Syndrome
Decatur : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Dothan : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Huntsville : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Huntsville : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Huntsville : Medical Affiliated Research Center, Inc.
Irritable Bowel Syndrome
Mobile : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Montgomery : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Montgomery : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Sheffield : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Tuscaloosa : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Arizona
Glendale : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Glendale : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Glendale : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Mesa : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Phoenix : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Phoenix : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Phoenix : Arizona Research Center
Irritable Bowel Syndrome - Diarrhea
Tucson : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Tucson : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Arkansas
Jonesboro : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Little Rock : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Little Rock : Lynn Institute of the Ozarks
Do you experience abdominal pain, bowel urgency and loose stools …due to Irritable Bowel Syndrome with Diarrhea or IBS-D? If so, please call the Lynn Institute at 501-975-2000.
Little Rock : Lynn Institute of the Ozarks
IBS-Diarrhea Patients
Sherwood : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
California
Anaheim : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Anaheim : Anaheim Clinical Trials (ACT)
Do you suffer from Irritable Bowel Syndrome?
Anaheim : Anaheim Clinical Trials (ACT)
Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS) needed for a clinical research trial
Bell Gardens : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Burbank : Providence Clinical Research
A research study evaluating an investigational medication in the treatment of Irritable Bowel Syndrome (also known as IBS).
Carmichael : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Chula Vista : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Cypress : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Encinitas : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Encinitas : Diagnamics, Inc.
This study will investigate the effects of 4-week probiotic supplementation on whole gut transit time and gastrointestinal symptoms in adults with constipation-predominant irritable bowel syndrome (IBS-C).
Garden Grove : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Garden Grove : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Garden Grove : Digestive & Liver Disease Specialists
This study will investigate the effects of 4-week probiotic supplementation on whole gut transit time and gastrointestinal symptoms in adults with constipation-predominant irritable bowel syndrome (IBS-C).
Huntington Beach : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Irvine : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
La Mesa : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
La Mirada : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Laguna Hills : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Lakewood : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Lincoln : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Long Beach : CNS Network
A Phase III study investigating a new treatment for Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
Long Beach : CNS Network
A Phase III study investigating a new treatment for Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
Long Beach : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Los Angeles : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Newport Beach : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
North Hollywood : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Northridge : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Pasadena : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Sacramento : Sutter Institute for Medical Research (SIMR)
Irritable Bowel Syndrome
San Diego : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
San Diego : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
San Diego : Wetlin Research Associates, Inc.
Do you suffer from Irritable Bowel Syndrome?
San Diego : Encompass Clinical Research
IBS...Irritable Bowel Syndrome
San Diego : Research Site
Irritable Bowel Syndrome (IBS) Diarrhea Clinical Trial
San Francisco : SPRIM
This study will investigate the effects of 4-week probiotic supplementation on whole gut transit time and gastrointestinal symptoms in adults with constipation-predominant irritable bowel syndrome (IBS-C).
San Gabriel : California Center for Clinical Research
A phase 3 study evaluating the effectiveness of study drug in the treatment of patients with Diarrhea-Predominant Irritable Bowel Syndrome.
San Gabriel : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Santa Ana : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Spring Valley : Encompass Clinical Research
IBS...Irritable Bowel Syndrome
Torrance : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Ventura : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Walnut Creek : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Westlake Village : Westlake Medical Research
This study will investigate the effects of 4-week probiotic supplementation on whole gut transit time and gastrointestinal symptoms in adults with constipation-predominant irritable bowel syndrome (IBS-C).
Colorado
Colorado Springs : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Denver : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Denver : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Wheat Ridge : Western States Clinical Research, Inc.
A RESEARCH STUDY FOR WOMEN AND MEN WITH DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNROME (IBS-D) We are seeking study volunteers 18-70 years of age who have been diagnosed with IBS-D for at least the last 3 months.
Connecticut
Millford : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Waterbury : Chase Medical Research, LLC
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome.
Florida
Aventura : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Boca Raton : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Boca Raton : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Boynton Beach : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Bradenton : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Brooksville : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Clearwater : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Clearwater : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Cooper City : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Coral Springs : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Deland : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Eustis : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Fort Lauderdale : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Haileah : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Hialeah : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Hialeah : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Jacksonville : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Jacksonville : IMA Research
Study to Evaluate the Efficacy, Safety, and Tolerability of XXXX in the Treatment Irritable Bowel Syndrome with Diarrhea
Jupiter : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Lauderdale Lakes : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Melbourne : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Miami : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Miami : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Miami : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Miami : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Miami : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Miami : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Miami : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Miramar : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
New Port Richey : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Orlando : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Palm Harbor : Advanced Gastroenterology Associates
Diarrhea-Predominant Irritable Bowel Syndrome
Panama City : Emerald Coast Research Associates
Volunteers needed, experiencing Irritable Bowel Syndrome (IBS) with constipation to participate in a research study.
Plant City : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Port Orange : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Port Orange : Accord Clinical Research, LLC
Do You Have Irritable Bowel Syndrome (Diarrhea)
Port Orange : Accord Clinical Research, LLC
Females With Irritable Bowel Syndrome (IBS)
South Miami : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
St. Petersburg : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Tamarac : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Tampa : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Tampa : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Tampa : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Wellington : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Wellington : Venra Clinical Studies, LLC
Irritable Bowel Syndrome
West Palm Beach : Palm Beach Research Center
If you have diarrhea and abdominal discomfort you may be eligible for this study
Winter Haven : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Winter Park : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Georgia
Alpharetta : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Athens : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Atlanta : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Atlanta : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Atlanta : Radiant Research - Atlanta
Clinical Research Study for IBS (with Diarrhea)
Blue Ridge : River Birch Research Alliance, LLC
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Columbus : Southeast Regional Research Group - Columbus
IBS-d
Duluth : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Dunwoody : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Dunwoody : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Johns Creek : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Lawrenceville : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Macon : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Marietta : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Snellivlle : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Stockbridge : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Suwanee : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Idaho
Boise : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Eagle : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Idaho Falls : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Meridian : Advanced Clinical Research, ID
Are diarrhea and abdominal discomfort putting a cramp in your lifestyle?
Meridian : Advanced Clinical Research, ID
Do you have irritable bowel syndrome with diarrhea?
Meridian : Advanced Clinical Research, ID
Running to the bathroom again because you have diarrhea caused by irritable bowel syndrome?
Illinois
Addison : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Addison : Biofortis Clinical Research
Do you suffer from IBS-d?
Addison : Biofortis Clinical Research
Suffering with IBS?
Arlington Heights : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Bourbonnais : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Bourbonnais : Healthcare Research Network
Irritable Bowel Syndrome (IBS) study
Champaign : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Chicago : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Chicago : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Evergreen Park : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Oak Lawn : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Springfield : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Indiana
Brownsburg : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Evansville : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Evansville : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Granger : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Kansas
Newton : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Pratt : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Shawnee : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Topeka : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Wichita : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Kentucky
Bowling Green : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Lexington : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Lexington : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Lexington : Kentucky Medical Research
IBS
Lexington : Kentucky Medical Research
IBS
Lexington : Central Kentucky Research Associates
IBS with Diarrhea
Owensboro : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Paducah : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Louisiana
Bossier City : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Lake Charles : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Monroe : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Maryland
Chevy Chase : Metropolitan Gastroenterology Group, PC Chevy Chase Clinical Research
The Pain and Discomfort of Irritable Bowel Syndrome
Chevy Chase : Chevy Chase Clinical Research
This study will investigate the effects of 4-week probiotic supplementation on whole gut transit time and gastrointestinal symptoms in adults with constipation-predominant irritable bowel syndrome (IBS-C).
Hagerstown : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Hollywood : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Towson : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Towson : Spectrum Clinical Research, Inc.
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Massachusetts
Boston : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Brockton : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Brockton : Beacon Clinical Research
Are you suffering from irritable bowel syndrome (IBS) ?
Brockton : Beacon Clinical Research
Have you or someone you know been diagnosed with Irritable Bowel Syndrome?
Fall River : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Watertown : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Watertown : MedVadis Research Corporation
A research study to evaluate the safety and effectiveness of an experimental medication compared to placebo (an inactive substance) for individuals with irritable bowel syndrome with diarrhea, or IBS-D.
Watertown : MedVadis Research Corporation
A research study to evaluate the safety and effectiveness of an experimental medication compared to placebo (an inactive substance) for individuals with irritable bowel syndrome with diarrhea, or IBS-D.
Michigan
Ann Arbor : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Ann Arbor : ClinSite, LLC
Suffering from Irritable Bowel Syndrome (IBS)?
Bay City : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Buckley : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Cadillac : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Grand Rapids : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Kalamazoo : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Pinconning : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Traverse City : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Troy : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Minnesota
Chaska : Ridgeview Research
Irritable Bowel Syndrome with Diarrhea
Fridley : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Plymouth : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Mississippi
Biloxi : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Missouri
Hazelwood : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Hazelwood : Healthcare Research Network
Irritable Bowel Syndrome (IBS) study
Mexico : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
St. Louis : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
St. Louis : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
St. Louis : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
St. Peters : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Montana
Billings : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Nebraska
Bellevue : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Elkhorn : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Fremont : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Lincoln : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Omaha : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Omaha : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Nevada
Las Vegas : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Las Vegas : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Reno : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
New Jersey
Blackwood : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Edison : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Edison : Anderson & Collins Clinical Research, Inc.
Irritable Bowel Syndrome?
Egg Harbor Township : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Elizabeth : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Elizabeth : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Marlton : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
New Mexico
Albuquerque : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Albuquerque : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Albuquerque : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
New York
Endwell : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Endwell : Regional Clinical Research, Inc.
Irritable Bowel Syndrome is a long term disorder that disrupts the lives of more than 5 million Americans. Are you a Woman who suffers with this condition?
Flushing : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Great Neck : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
New Hyde Park : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
New Hyde Park : Parker Jewish Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
New York : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
New York : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
New York : Biomedical Research Alliance of New York, LLC
Diarrhea Predominant Irritable Bowel Syndrome
Poughkeepsie : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
North Carolina
Asheville : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Calabash : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Charlotte : PMG Research of Charlotte
Do you experience abdominal discomfort or pain with your diarrhea?
Charlotte : PMG Research of Charlotte
IBS: Do you experience abdominal discomfort or pain with your diarrhea?
Dunn : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Greensboro : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Greensboro : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Hickory : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Hickory : PMG Research of Hickory
Do you experience abdominal discomfort or pain with your diarrhea?
Hickory : PMG Research of Hickory
Do you experience abdominal discomfort or pain with your diarrhea?
Hickory : PMG Research of Hickory
IBS: Do you experience abdominal discomfort or pain with your diarrhea?
Huntersville : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Kinston : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Mount Pleasant : PMG Research of Charleston
Do You Suffer from Abdominal Pain that is Associated with Chronic Diarrhea?
Raleigh : PMG Research of Raleigh
Do you experience abdominal discomfort or pain with your diarrhea?
Raleigh : Wake Research Associates
Irritable Bowel Syndrome with Diarrhea
Raleigh : Wake Research Associates
Irritable Bowel Syndrome with Diarrhea
Raleigh : Wake Research Associates
Irritable Bowel Syndrome with Diarrhea or IBS-D?
Tabor City : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Wilmington : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Winston Salem : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Winston Salem : PMG Research of Winston-Salem
Do You Suffer from Abdominal Pain that is Associated with Chronic Diarrhea?
Winston Salem : PMG Research of Winston-Salem
Got IBS? With diarrhea.
Winston-Salem : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Winston-Salem : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Winston-Salem : PMG Research of Winston-Salem
IBS: Do you experience abdominal discomfort or pain with your diarrhea?
Ohio
Akron : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Akron : Radiant Research - Akron
Clinical Research for Irritable Bowel Syndrome (IBS)
Beavercreek : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Cincinnati : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Cincinnati : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Cincinnati : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Cincinnati : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Cincinnati : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Cleveland : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Cleveland : Rapid Medical Research, Inc. (RMR)
Are diarrhea and abdominal discomfort putting a cramp in your lifestyle?
Cleveland : Rapid Medical Research, Inc. (RMR)
Running to the bathroom again because you have diarrhea caused by irritable bowel syndrome?
Columbus : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Columbus : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Columbus : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Columbus : Radiant Research - Columbus
Clinical Research for People with Irritable Bowel Syndrome with Diarrhea
Dayton : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Dayton : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Groveport : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Kettering : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Maumee : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Springfield : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Tiffin : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Toledo : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Oklahoma
Norman : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Oklahoma City : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Oklahoma City : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Oklahoma City : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Oklahoma City : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Tulsa : Vital Prospects Clinical Research Institute, P.C.
Irritable Bowel Syndrome (IBS)
Oregon
Portland : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Portland : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Salem : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Pennsylvania
Carnegie : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Philadelphia : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Pittsburgh : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Pittsburgh : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Scottdale : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Sellersville : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Uniontown : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Uniontown : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Uniontown : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Rhode Island
Warwick : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
South Carolina
Anderson : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Columbia : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Columbia : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Columbia : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Easley : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Greenville : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Mt. Pleasant : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Mt. Pleasant : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Mt. Pleasant : Coastal Carolina Research Center
Irritable Bowel Syndrome - diarrhea predominant clinical trial.
North Myrtle Beach : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
South Dakota
Rapid City : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Tennessee
Athens : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Bristol : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Bristol : PMG Research of Bristol
IBS: Irritable Bowel Syndrome Research Study
Chattanooga : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Chattanooga : ClinSearch, LLC
Treatment of Patients With Irritable Bowel Syndrome With Diarrhea
Clarksville : Alpha Clinical Research, LLC
Irritable Bowel Syndrome?
Columbia : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Jackson : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Jackson : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Knoxville : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Nashville : Dial Research Associates, Inc.
Irritable Bowel Syndrome-Diarrhea
Smryna : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Texas
Austin : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Beaumont : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Bedford : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Bellaire : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Carrollton : Research Across America
This study will investigate the effects of 4-week probiotic supplementation on whole gut transit time and gastrointestinal symptoms in adults with constipation-predominant irritable bowel syndrome (IBS-C).
Corsicana : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Dallas : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Dallas : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Dallas : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Dallas : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Dallas : ACRC TRIALS
DIARRHEA predominant Irritable Bowel Syndrome (Abdominal Pain, Bloating, and Diarrhea)?
Dallas : Research Across America
This study will investigate the effects of 4-week probiotic supplementation on whole gut transit time and gastrointestinal symptoms in adults with constipation-predominant irritable bowel syndrome (IBS-C).
Fort Worth : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Frisco : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Grapevine : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Houston : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Houston : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Houston : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Houston : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Houston : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Houston : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Houston : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Houston : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Houston : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Houston : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Hurst : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Katy : Research Across America
This study will investigate the effects of 4-week probiotic supplementation on whole gut transit time and gastrointestinal symptoms in adults with constipation-predominant irritable bowel syndrome (IBS-C).
Plano : North Texas Family Medicine
This study will investigate the effects of 4-week probiotic supplementation on whole gut transit time and gastrointestinal symptoms in adults with constipation-predominant irritable bowel syndrome (IBS-C).
Plano : Village Health Partners
This study will investigate the effects of 4-week probiotic supplementation on whole gut transit time and gastrointestinal symptoms in adults with constipation-predominant irritable bowel syndrome (IBS-C).
Richmond : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
San Antonio : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
San Antonio : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
San Antonio : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
San Antonio : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
San Antonio : Quality Research Inc.
Diarrhea Predominant Irritable Bowel Syndrome
San Antonio : Sun Research Institute
Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS) needed for a clinical research trial
Spring : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Utah
Bountiful : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Clinton : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Salt Lake City : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Salt Lake City : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Salt Lake City : Optimum Clinical Research, Inc.
Irritable Bowel Syndrome - Diarrhea Predominant
West Jordan : Advanced Clinical Research, UT
Are diarrhea and abdominal discomfort putting a cramp in your lifestyle?
West Jordan : Advanced Clinical Research, UT
Do you have irritable bowel syndrome with diarrhea?
West Jordan : Advanced Clinical Research, UT
Running to the bathroom again because you have diarrhea caused by irritable bowel syndrome?
West Valley City : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Virginia
Alexandria : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Charlottesville : Charlottesville Medical Research
Do you suffer from IBS-D?
Christiansburg : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Midlothian : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Midlothian : Virginia Research Center
Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (Protocol JNJ-27018966IBS3002)
Newport News : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Norfolk : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Norfolk : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Richmond : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Richmond : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Richmond : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Richmond : Virginia Research Center
Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (Protocol JNJ-27018966IBS3002)
Washington
Bellevue : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Tacoma : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
West Virginia
Charleston : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Wisconsin
Monroe : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Canada
Burlington : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Cambridge : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Corunna : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Guelph : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Hawkesbury : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Kelowna : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Kelowna, BC : Okanagan Clinical Trials
Do you experience diarrhea-predominant irritable bowel syndrome?
London : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Newmarket : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Sarnia : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Sudbury : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Toronto : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Toronto : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Puerto Rico
San Juan : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
United Kingdom
Balham : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Bath : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Bath : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Blackpool : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Blackpool : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Bolton : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Bridgwater : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Chesterfield : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Chestfield : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Chippenham : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Chippenham : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Cleveleys : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Cornwall : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Coventry : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Dorking, Surrey : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Ely : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Exmouth : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Fleetwood : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Fowey : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Frome : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Glasgow : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Harrow : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Haxey : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Hinkley : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Lancaster : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Leamington Spa : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Letchworth : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
London : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Midsomer Norton : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Nantwich : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Salford : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Sedbergh : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Shrewsbury : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Shrewsbury : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Southampton : Research Center
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Trowbridge : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Trowbridge : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Warminster : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Warwickshire : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Watford, Herts : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Wellingborough : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
Wymondham, Norfolk : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
York : Research Center Updated
A randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
